Evidence map›Paper›PMID 29584887›Full record

ArticleJournal of radiation research2018

National survey of myeloablative total body irradiation prior to hematopoietic stem cell transplantation in Japan: survey of the Japanese Radiation Oncology Study Group (JROSG).

Naoya Ishibashi, Toshinori Soejima, Hiroki Kawaguchi, Takeshi Akiba, Masatoshi Hasegawa, Kouichi Isobe, Hitoshi Ito, Michiko Imai, Yasuo Ejima, Masaharu Hata and 6 more

Open access · goldAbstract read
In one paragraph

Article in Journal of radiation research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Two compound techniques for total body irradiation.Technical innovations & patient support in radiation oncology · 2022
    Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 12 institutions in 1 country.

Naoya IshibashiDepartment of Radiology, Nihon University School of Medicine, 30-1 Oyaguchi Kami-cho, Itabashi-ku, Tokyo, Japan.
Toshinori SoejimaDepartment of Radiation Oncology, Hyogo Cancer Center, Akashi, Japan.
Hiroki KawaguchiDivision of Radiation Oncology, Kobe University Graduate School of Medicine, Kobe, Japan.
Takeshi AkibaDepartment of Radiation Oncology, Tokai University, School of Medicine, Isehara, Japan.
Masatoshi HasegawaDepartment of Radiation Oncology, Nara Medical University, Kashihara, Japan.
Kouichi IsobeDepartment of Radiology, Toho University Sakura Medical Center, Chiba, Japan.
Hitoshi ItoDepartment of Radiation Oncology, Kyoto Katsura Hospital, Kyoto, Japan.
Michiko ImaiDepartment of Radiation Oncology, Iwata City General Hospital, Shizuoka, Japan.
Yasuo EjimaDivision of Radiation Oncology, Kobe University Graduate School of Medicine, Kobe, Japan.
Masaharu HataDivision of Radiation Oncology, Department of Oncology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Keisuke SasaiDepartment of Radiation Oncology, Faculty of Medicine, Juntendo University, Tokyo, Japan.
Emiko ShimodaDepartment of Radiation Oncology, Nara Medical University, Kashihara, Japan.
Toshiya MaebayashiDepartment of Radiology, Nihon University School of Medicine, 30-1 Oyaguchi Kami-cho, Itabashi-ku, Tokyo, Japan.
Masahiko OguchiDepartment of Radiation Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Tetsuo AkimotoDivision of Radiation Oncology and Particle Therapy, National Cancer Center Hospital East, Kashiwa, Japan.
Japanese Radiation Oncology Study Group
Kobe University · JPNara Medical University · JPNihon University · JPHyogo Prefectural Cancer Center · JPIwata City Hospital · JPJapanese Foundation For Cancer Research · JPJuntendo University · JPKyoto Katsura Hospital · JPNational Cancer Center Hospital East · JPToho University · JPTokai University · JPYokohama City University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A myeloablative regimen that includes total-body irradiation (TBI) before hematopoietic stem cell transplantation results in higher patient survival rates than achieved with regimens without TBI. The TBI protocol, however, varies between institutions. In October 2015, the Japanese Radiation Oncology Study Group initiated a national survey of myeloablative TBI (covering 2010-2014). Among the 186 Japanese institutions performing TBI, 90 (48%) responded. The 82 institutions that had performed myeloablative TBI during this period treated 2698 patients with malignant disease [leukemia (2082 patients, 77.2%), malignant lymphoma (378, 14%)] and 37 with non-malignant disease [severe aplastic anemia (20, 54%), inborn errors of metabolism (5, 14%)]. A linear accelerator was used at all institutions. The institutions were divided into 41 large and 41 small institutions based on the median number of patients. The long source-surface distance technique was the method of choice in the 34 institutions (82.9%) and the moving-couch technique in the 7 (17.1%) in the large institutions. The schedules most routinely used by the participating institutions consisted of 12 Gy/6 fractions/3 days (26 institutions, 63.5%) in the large institutions. The dose rate varied from 5 to 26 cGy/min. The lungs and lenses were routinely shielded in 23 large institutions (56.1%), and only the lungs in 9 large institutions (21.9%). At lung-shielding institutions, the most frequent maximum acceptable total dose for the lungs was 8 Gy (19 institutions, 27.5%). Our results reveal considerable differences in the TBI methods used by Japanese institutions and thus the challenges in designing multicenter randomized trials based on TBI.

Indexed as

Hematopoietic Stem Cell TransplantationRadiation OncologySurveys and QuestionnairesWhole-Body IrradiationDose Fractionation, RadiationHumansJapanTime Factors

Identifiers

PMID29584887
PMCPMC6054214
OpenAlexW2793627803

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.